Abstract:Neuromuscular disorders are often caused by heterogeneous mutations in large, structurally complex genes. Targeting compensatory modifier genes could be beneficial to improve disease phenotypes. Here we report a mutation-independent strategy to upregulate the expression of a disease-modifying gene associated with congenital muscular dystrophy type 1A (MDC1A) using the CRISPR activation system in mice. MDC1A is caused by mutations in LAMA2 that lead to nonfunctional laminin-α2, which compromises the stability of muscle fibres and the myelination of peripheral nerves. Transgenic overexpression of Lama1, which encodes a structurally similar protein called laminin-α1, ameliorates muscle wasting and paralysis in mouse models of MDC1A, demonstrating its importance as a compensatory modifier of the disease<a href="/articles/s41586-019-1430-x#ref-CR1">1</a>. However, postnatal upregulation of Lama1 is hampered by its large size, which exceeds the packaging capacity of vehicles that are clinically relevant for gene therapy. We modulate expression of Lama1 in the dy2j/dy2j mouse model of MDC1A using an adeno-associated virus (AAV9) carrying a catalytically inactive Cas9 (dCas9), VP64 transactivators and single-guide RNAs that target the Lama1 promoter. When pre-symptomatic mice were treated, Lama1 was upregulated in skeletal muscles and peripheral nerves, which prevented muscle fibrosis and paralysis. However, for many disorders it is important to investigate the therapeutic window and reversibility of symptoms. In muscular dystrophies, it has been hypothesized that fibrotic changes in skeletal muscle are irreversible. However, we show that dystrophic features and disease progression were improved and reversed when the treatment was initiated in symptomatic dy2j/dy2j mice with apparent hindlimb paralysis and muscle fibrosis. Collectively, our data demonstrate the feasibility and therapeutic benefit of CRISPR–dCas9-mediated upregulation of Lama1, which may enable mutation-independent treatment for all patients with MDC1A. This approach has a broad applicability to a variety of disease-modifying genes and could serve as a therapeutic strategy for many inherited and acquired diseases.

Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia

Long-term muscle-specific overexpression of DOK7 in mice using AAV9-tMCK-DOK7

A mutation in DOK7 in congenital myasthenic syndrome forms aggresome in cultured cells, and reduces DOK7 expression and MuSK phosphorylation in patient-derived iPS cells

A spontaneous missense mutation in the chromodomain helicase DNA-binding protein 8 (CHD8) gene: a novel association with congenital myasthenic syndrome

Disrupting of E79 and K138 Interaction is Responsible for Human Muscle Creatine Kinase Deficiency Diseases

Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes

Modulation of the Acetylcholine Receptor Clustering Pathway Improves Neuromuscular Junction Structure and Muscle Strength in a Mouse Model of Congenital Myasthenic Syndrome

Activation of Muscle-Specific Kinase (MuSK) Reduces Neuromuscular Defects in the Delta7 Mouse Model of Spinal Muscular Atrophy (SMA)

A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene

An Agrin Minigene Rescues Dystrophic Symptoms in a Mouse Model for Congenital Muscular Dystrophy

Nerve Pathology is Prevented by Linker Proteins in Mouse Models for LAMA2-related Muscular Dystrophy.

Aberrant Myokine Signaling in Congenital Myotonic Dystrophy

A Mechanism in Agrin Signaling Revealed by a Prevalent Rapsyn Mutation in Congenital Myasthenic Syndrome.

Congenital myopathies: pathophysiological mechanisms and promising therapies

Novel compound missense variants in MUSK impair LRP4-MUSK-DOK7 complex associated with congenital myasthenic syndrome 9 and insights into genotype-phenotype correlation

The severity of MUSK pathogenic variants is predicted by the protein domain they disrupt

Mechanism of action and therapeutic route for a muscular dystrophy caused by a genetic defect in lipid metabolism

DOK7 Promotes NMJ Regeneration After Nerve Injury

Suppression of myopathic lamin mutations by muscle-specific activation of AMPK and modulation of downstream signaling

APC2CDH1negatively Regulates Agrin Signaling by Promoting the Ubiquitination and Proteolytic Degradation of DOK7

Agonist antibody to MuSK protects mice from MuSK myasthenia gravis